In Canada, a subsidiary of the pharmaceutical giant has introduced Propranolol LA capsules in dosages of 60 mg, 80 mg, 120 mg, and 160 mg.
Following news that Lupin’s subsidiary had introduced a medication to promote heart health in Canada, the drug giant’s shares increased by almost 2% in early trade on Wednesday. Separately, the phama business announced to exchanges on Tuesday that the United States Food and medication Administration (U.S. FDA) had approved its abbreviated new medication application for Pirfenidone Capsules used to treat a specific lung illness.
Lupin shares began 1.9% higher at 1,118.15 on the BSE than they did at their previous closing price of 1,097.05 on the BSE, buoyed by the news. Approximately 8,500 shares have been traded over the counter in the first two hours of trading, increasing the market capitalization to $50,223 crore.